Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
18 November 2020 - 01:00PM
Business Wire
- Co-development program will utilize next-generation digital
pathology platform and AI-based technology to provide real-time
genomic testing results
- Partnership to create new products enabling faster access to
predictive information in treatment planning for patients with
breast cancer
Agendia, Inc., a world leader in precision oncology for breast
cancer, and Paige, a global leader in AI-based digital diagnostics,
today announced a first of its kind strategic partnership that will
redefine precision oncology. The partnership will enable
co-development of treatment planning tools that integrate the
cloud-based Paige Platform with genomic information from Agendia’s
proprietary MammaPrint® and BluePrint® diagnostic tests for
patients with breast cancer. These new products will enable faster
access to predictive and prognostic information along the entire
continuum of care, from diagnosis and early intervention to
metastatic treatment planning.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201118005250/en/
“Paige’s digital pathology platform is truly transformational
for oncology and will catapult diagnostics forward as a whole. This
partnership defines the democratization of treatment planning tools
by accelerating access to these tests and the essential insights
they provide for more patients globally,” said Mark Straley, Chief
Executive Officer of Agendia. “Our goal is to provide same-day
turnaround in most cases, enable earlier intervention, preserve
limited biopsy or surgical tissue specimens, and extend key
benefits to physicians and their patients with access to testing in
countries where tissue ‘send out’ is not allowed. Whether a patient
is in Manhattan or Mumbai, the ability to get real-time and
accurate results from Agendia’s MammaPrint and BluePrint tests will
improve how we are treating breast cancer today.”
The initial focus of the collaboration will be the development
of digital tests for early treatment planning where genomic testing
has played an essential role in determining recurrence risk and
tumor biology as doctors and their patients make decisions about
the path ahead. This can be especially important for patients with
operable breast cancer. Beyond early intervention, AI-derived
biomarkers will be used to augment genomic testing in the
metastatic setting where a multitude of therapeutic options can add
to the complexity of treatment planning.
“As the first company to receive FDA clearance, FDA breakthrough
designation and two CE marks for digital and computational
pathology products, Paige is delivering next-generation digital
diagnostics that redefine how we approach cancer care,” said Leo
Grady, Ph.D., Chief Executive Officer of Paige. “By combining our
unique capabilities with Agendia’s leadership in breast cancer, we
believe this innovative partnership can achieve our shared goal of
transforming clear and actionable information into precision
treatment for better patient outcomes. It will be the first of many
AI-based diagnostic tests to come.”
For more information, please visit Agendia.com and Paige.ai.
About Agendia
Agendia is a precision oncology company headquartered in Irvine,
California, committed to bringing early stage breast cancer
patients and their physicians the information they need to make the
best decisions for the full treatment journey. The company
currently offers two commercially-available genomic profiling
tests, supported by the highest levels of clinical and real world
evidence, that provide comprehensive genomic information that can
be used to identify the most effective breast cancer treatment
possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the
only FDA-cleared risk of recurrence test backed by peer-reviewed,
prospective outcome data and inclusion in both national and
international treatment guidelines. BluePrint®, the 80-gene
molecular subtyping assay, is the only commercially-available test
that evaluates the underlying biology of a tumor to determine what
is driving its growth. Together, MammaPrint® and BluePrint® provide
a comprehensive genomic profile to help physicians make more
informed decisions in the pre- and post-operative treatment
settings.
By developing evidence-based novel genomic tests and conducting
groundbreaking research while building an arsenal of data that will
help treat breast cancer, Agendia aims to improve patient outcomes
and support the evolving clinical needs of breast cancer patients
and their physicians every step of the way, from initial diagnosis
to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical
specimens to inform pre- and post-operative treatment decisions.
For more information on Agendia’s assays and ongoing trials, please
visit www.agendia.com
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues
from Memorial Sloan Kettering Cancer Center (MSKCC). The company
builds computational pathology products designed so patients and
their care teams can make effective, more informed treatment
decisions. With this new class of AI-based technologies positioned
to drive the future of diagnostics, Paige created a platform to
deliver this novel technology to pathologists to transform their
workflow and increase diagnostic confidence and productivity.
Paige’s products deliver insights to pathologists and oncologists
so they can arrive efficiently at more precise diagnoses for
patients. Paige is the first company to receive FDA breakthrough
designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai,
https://www.paigeplatform.com , Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201118005250/en/
For Media: Terri Clevenger Westwicke/ICR Healthcare PR
Tel: 203.856.4326 Terri.Clevenger@icrinc.com For Agendia
Investors: Mike Cavanaugh Westwicke/ICR Healthcare IR Tel:
617.877.9641 Mike.Cavanaugh@westwicke.com